American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24)

Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.

The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.

Patients with ST-segment elevation myocardial infarction (STEMI)-related cardiogenic shock may benefit from a significantly higher survival rate at 6 months through the routine use of a microaxial flow pump in combination with standard care as compared with standard care alone, as shown in a study presented at the recent ACC.24.